Ikarashi Daiki, Obara Wataru
Dept. of Urology, Iwate Medical University School of Medicine.
Gan To Kagaku Ryoho. 2024 Jul;51(7):691-694.
Most recently, the antibody-drug conjugate, enfortumab vedotin, has been covered by insurance for the treatment of unresectable or metastatic urothelial carcinoma after chemotherapy and immune checkpoint inhibitors, and has significantly changed the pharmacotherapy for urothelial carcinoma in clinical practice. Recently, several reports demonstarated the efficacy and safety of enfortumab vedotin in real-world clinical practice, highlighting its current status and challenges. In addition, the combination of enfortumab vedotin and pembrolizumab for the treatment of untreated unresectable or metastatic urothelial carcinoma has received expedited approval by the FDA and is expected to become a key drug in urothelial carcinoma.
最近，抗体药物偶联物恩杂鲁胺已被纳入医保，用于治疗化疗和免疫检查点抑制剂治疗后的不可切除或转移性尿路上皮癌，并在临床实践中显著改变了尿路上皮癌的药物治疗。最近，几份报告证明了恩杂鲁胺在真实世界临床实践中的疗效和安全性，突出了其现状和挑战。此外，恩杂鲁胺与帕博利珠单抗联合用于治疗未经治疗的不可切除或转移性尿路上皮癌已获得美国食品药品监督管理局的加速批准，有望成为尿路上皮癌的关键药物。
